Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 35.e21-35.e30

  Lamm, Donald ^a   Brausi, Maurizio ^b   O'Donnell, Michael A ^c   Witjes, J Alfred ^d  

^a BCG Oncology   (United States)

^b Nuovo Ospedale S Agostino   (Italy)

^c UNIVERSITY OF IOWA   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bacillus Calmette Gu rin; Chemotherapy; Immunotherapy; Interferon alfa; Intravesical therapy; Non muscle invasive bladder cancer

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CARCINOMA IN SITU; CYSTECTOMY; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; MORBIDITY; MYCOBACTERIUM BOVIS BCG; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; TRANSURETHRAL RESECTION; TREATMENT FAILURE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; ONCOLOGY; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME; TRENDS; URINARY BLADDER NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; CLINICAL TRIALS AS TOPIC; CYSTECTOMY; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MEDICAL ONCOLOGY; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84890806849     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.02.010     Document Type: Review

References (59)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Brausi M., Witjes J.A., Lamm D., et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011, 186:2158-2167.
3. Babjuk M., Oosterlinck W., Sylvester R., et al. European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59:997-1008.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Bladder cancer. Version 2.2012. Available at: 〈〉; [accessed 19.12.12]. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
5. Torti F.M., Shortliffe L.D., Williams R.D., et al. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol 1988, 6:476-483.
6. Glashan R.W. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 1990, 144:658-661.
7. Malmström P.U. A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 2002, 89:681-686.
8. Sylvester R.J., Brausi M.A., Kirkels W.J., et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010, 57:766-773.
9. Lamm D., Colombel M., Persad R., et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol Suppl 2008, 7:651-666.
10. Giannakopoulos S., Gekas A., Alivizatos G., Sofras F., Becopoulos T., Dimopoulos C. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br J Urol 1998, 82:829-834.
11. Portillo J., Martin B., Hernandez R., et al. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology 1997, 49:187-190.
12. Boccardo F., Cannata D., Rubagotti A., et al. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J Clin Oncol 1994, 12:7-13.
13. Rajala P., Kaasinen E., Raitanen M., Liukkonen T., Rintala E. Perioperative single dose instillation of epirubicin or interferon-α after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study-FinnBladder III long-term results. J Urol 2002, 168:981-985. Finnbladder Group.
14. Jimenez-Cruz J.F., Vera-Donoso C.D., Leiva O., et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha. Urology 1997, 50:529-535.
15. Babjuk M. New insights in intravesical treatment for intermediate- and high-risk non-muscle-invasive urothelial bladder carcinoma. Eur Urol 2010, 57:774-776.
16. Sylvester R.J., van der Meijden A.P., Witjes J.A., Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005, 174:86-91.
17. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163:1124-1129.
18. Lamm D.L. Carcinoma in situ. Urol Clin North Am 1992, 19:499-508.
19. Hinotsu S., Akaza H., Naito S., et al. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int 2011, 108:187-195.
20. Brausi M., Oddens J., Sylvester R., et al. Bacillus Calmette-Guerin: one third dose versus full dose and one year versus three years of maintenance. Final results of EORTC GU Cancers Group randomized trial 30962 in non muscle invasive bladder cancer. Abstract 1665. J Urol 2012, 187:e672.
21. Sylvester R.J., van der M.A., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168:1964-1970.
22. Böhle A., Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004, 63:682-686.
23. Brake M., Loertzer H., Horsch R., Keller H. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer. Urology 2000, 55:673-678.
24. Morales A. Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. J Urol 1984, 132:457-459.
25. Catalona W.J., Hudson M.A., Gillen D.P., Andriole G.L., Ratliff T.L. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 1987, 137:220-224.
26. Malmström P.U., Wijkström H., Lundholm C., Wester K., Busch C., Norlén B.J. 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999, 161:1124-1127.
27. Steinberg G., Bahnson R., Brosman S., Middleton R., Wajsman Z., Wehle M. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000, 163:761-767.
28. Mohanty N.K., Nayak R.L., Vasudeva P., Arora R.P. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol 2008, 26:616-619.
29. Dalbagni G., Russo P., Bochner B., et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guéin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006, 24:2729-2734.
30. Di Lorenzo G., Perdonà S., Damiano R., et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010, 116:1893-1900.
31. Addeo R., Caraglia M., Bellini S., et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 2010, 28:543-548.
32. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003, 170:777-782.
33. Nativ O., Witjes J.A., Hendricksen K., et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 2009, 182:1313-1317.
34. ® working party. World J Urol 2009, 27:319-324.
35. Schenkman E., Lamm D.L. Superficial bladder cancer therapy. Sci World J 2004, 4(Suppl. 1):387-399.
36. O'Donnell M.A. Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer. Expert Rev Anticancer Ther 2003, 3:809-821.
37. Kaempfer R., Gerez L., Farbstein H., et al. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 1996, 14:1778-1786.
38. de Reijke T.M., de Boer E.C., Kurth K.H., Schamhart D.H. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996, 155:477-482.
39. Poppas D.P., Pavlovich C.P., Folkman J., et al. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 1998, 52:268-275.
40. Ludwig A.T., Moore J.M., Luo Y., et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette-Guérin-induced antitumor activity. Cancer Res 2004, 64:3386-3390.
41. Luo Y., Chen X., Downs T.M., DeWolf W.C., O'Donnell M.A. IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol 1999, 162:2399-2405.
42. Moltó L., Carballido J., Manzano L., Reyes E., Olivier C., Alvarez-Mon M. Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder. Br J Cancer 1997, 75:1849-1853.
43. O'Donnell M.A., Luo Y., Chen X., Szilvasi A., Hunter S.E., Clinton S.K. Role of IL-12 in the induction and potentiation of IFN-γ in response to bacillus Calmette-Guérin. J Immunol 1999, 163:4246-4252.
44. Zhang Y., Khoo H.E., Esuvaranathan K. Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. J Urol 1999, 161:977-983.
45. Slaton J.W., Perrotte P., Inoue K., Dinney C.P., Fidler I.J. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999, 5:2726-2734.
46. Papageorgiou A., Dinney C.P., McConkey D.J. Interferon-α induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther 2007, 6:872-879.
47. Natsis K., Toliou T., Stravoravdi P., et al. Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study. Int J Clin Pharmacol Res 1997, 17:31-36.
48. Agarwal A., Agrawal U., Verma S., Mohanty N.K., Saxena S. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacol Immunotoxicol 2010, 32:348-356.
49. Downs T.M., Szilvasi A., O'Donnell M.A. Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B. J Urol 1997, 158:2311-2315.
50. Lamm D.L., Steg A., Boccon-Gibod L., et al. Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 1989, 310:335-355.
51. Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, Lamm DL. Bladder Cancer Genitourinary Oncology Study Group. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 2010;184:1915-19.
52. Punnen SP, Chin JL, Jewett MA. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can J Urol 2003;10:1790-15.
53. Lam J.S., Benson M.C., O'Donnell M.A., et al. Bacillus Calmete-Guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 2003, 21:354-360.
54. O'Donnell M.A., Krohn J., DeWolf W.C. Salvage intravesical therapy with interferon-α 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001, 166:1300-1305.
55. Joudi F.N., Smith B.J., O'Donnell M.A. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006, 24:344-348. National BCG-Interferon Phase 2 Investigator Group.
56. Joudi F.N., Smith B.J., O'Donnell M.A., Konety B.R. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 2006, 175:1634-1640.
57. Gallagher B.L., Joudi F.N., Maymí J.L., O'Donnell M.A. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy. Urology 2008, 71:297-301.
58. Rosevear H.M., Lightfoot A.J., Birusingh K.K., Maymi J.L., Nepple K.G., O'Donnell M.A. National BCG/Interferon Investigator Group. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ. J Urol 2011, 186:817-823.
59. Margel D., Alkhateeb S.S., Finelli A., Fleshner N. Diminished efficacy of bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer. Urology 2011, 78:848-854.